Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Cross talk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistance.

Scheller M, Schönheit J, Zimmermann K, Leser U, Rosenbauer F, Leutz A.

J Exp Med. 2013 Oct 21;210(11):2239-56. doi: 10.1084/jem.20130706. Epub 2013 Oct 7.

2.

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.

Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, Sawyers CL, Weissman IL.

N Engl J Med. 2004 Aug 12;351(7):657-67.

3.

Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.

Xu XH, Gan YC, Xu GB, Chen T, Zhou H, Tang JF, Gu Y, Xu F, Xie YY, Zhao XY, Xu RZ.

J Zhejiang Univ Sci B. 2012 Nov;13(11):867-74. doi: 10.1631/jzus.B1200021.

4.

beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.

Hu Y, Chen Y, Douglas L, Li S.

Leukemia. 2009 Jan;23(1):109-16. doi: 10.1038/leu.2008.262. Epub 2008 Sep 25.

PMID:
18818703
5.

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.

Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.

Cancer Res. 2005 Oct 1;65(19):8912-9.

6.

Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML.

Heidel FH, Bullinger L, Feng Z, Wang Z, Neff TA, Stein L, Kalaitzidis D, Lane SW, Armstrong SA.

Cell Stem Cell. 2012 Apr 6;10(4):412-24. doi: 10.1016/j.stem.2012.02.017.

7.

The CML stem cell: evolution of the progenitor.

Stuart SA, Minami Y, Wang JY.

Cell Cycle. 2009 May 1;8(9):1338-43. Epub 2009 May 17.

8.

IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia.

Hu X, Yang D, Zimmerman M, Liu F, Yang J, Kannan S, Burchert A, Szulc Z, Bielawska A, Ozato K, Bhalla K, Liu K.

Cancer Res. 2011 Apr 15;71(8):2882-91. doi: 10.1158/0008-5472.CAN-10-2493. Epub 2011 Apr 12.

9.

CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression.

Schürch C, Riether C, Matter MS, Tzankov A, Ochsenbein AF.

J Clin Invest. 2012 Feb;122(2):624-38. doi: 10.1172/JCI45977. Epub 2012 Jan 9.

10.

Chronic myeloid leukemia blast crisis arises from progenitors.

Michor F.

Stem Cells. 2007 May;25(5):1114-8. Epub 2007 Jan 11.

11.

The transcription factor IRF8 counteracts BCR-ABL to rescue dendritic cell development in chronic myelogenous leukemia.

Watanabe T, Hotta C, Koizumi S, Miyashita K, Nakabayashi J, Kurotaki D, Sato GR, Yamamoto M, Nakazawa M, Fujita H, Sakai R, Fujisawa S, Nishiyama A, Ikezawa Z, Aihara M, Ishigatsubo Y, Tamura T.

Cancer Res. 2013 Nov 15;73(22):6642-53. doi: 10.1158/0008-5472.CAN-13-0802.

12.

Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis.

Yuan H, Wang Z, Li L, Zhang H, Modi H, Horne D, Bhatia R, Chen W.

Blood. 2012 Feb 23;119(8):1904-14. doi: 10.1182/blood-2011-06-361691. Epub 2011 Dec 29.

13.

Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation.

Abrahamsson AE, Geron I, Gotlib J, Dao KH, Barroga CF, Newton IG, Giles FJ, Durocher J, Creusot RS, Karimi M, Jones C, Zehnder JL, Keating A, Negrin RS, Weissman IL, Jamieson CH.

Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3925-9. doi: 10.1073/pnas.0900189106. Epub 2009 Feb 23.

14.

Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.

Bartholomeusz GA, Talpaz M, Kapuria V, Kong LY, Wang S, Estrov Z, Priebe W, Wu J, Donato NJ.

Blood. 2007 Apr 15;109(8):3470-8. Epub 2007 Jan 3.

15.

Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.

Casetti L, Martin-Lannerée S, Najjar I, Plo I, Augé S, Roy L, Chomel JC, Lauret E, Turhan AG, Dusanter-Fourt I.

Cancer Res. 2013 Apr 1;73(7):2052-8. doi: 10.1158/0008-5472.CAN-12-3955. Epub 2013 Feb 11.

16.

Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.

Kometani K, Aoki M, Kawamata S, Shinozuka Y, Era T, Taniwaki M, Hattori M, Minato N.

Cancer Res. 2006 Oct 15;66(20):9967-76.

17.

Chronic myelogenous leukemia: mechanisms underlying disease progression.

Shet AS, Jahagirdar BN, Verfaillie CM.

Leukemia. 2002 Aug;16(8):1402-11. Review.

18.

Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.

Morel F, Bris MJ, Herry A, Calvez GL, Marion V, Abgrall JF, Berthou C, Braekeleer MD.

Eur J Haematol. 2003 Apr;70(4):235-9.

PMID:
12656747
19.

A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.

Dash AB, Williams IR, Kutok JL, Tomasson MH, Anastasiadou E, Lindahl K, Li S, Van Etten RA, Borrow J, Housman D, Druker B, Gilliland DG.

Proc Natl Acad Sci U S A. 2002 May 28;99(11):7622-7.

20.

Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.

Lim S, Saw TY, Zhang M, Janes MR, Nacro K, Hill J, Lim AQ, Chang CT, Fruman DA, Rizzieri DA, Tan SY, Fan H, Chuah CT, Ong ST.

Proc Natl Acad Sci U S A. 2013 Jun 18;110(25):E2298-307. doi: 10.1073/pnas.1301838110. Epub 2013 Jun 4.

Supplemental Content

Support Center